Monjuvi® (tafasitamab-cxix)
for Lymphoma

Monjuvi (tafasitamab-cxix) is a targeted immunotherapy used to treat adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant. It is used with lenalidomide. Monjuvi is a CD19-directed cytolytic antibody that binds to CD19 on cancer cells, helping the immune system recognize and destroy them. It is also used for DLBCL arising from low-grade lymphoma.

Heart
Medication Guide Icon Medication Guide
Patient Website Icon Patient Website
Efficacy Data Icon Efficacy Data
New Articles Icon New Articles
Savings and Support Icon Savings and Support
Company MD Payments Icon Company MD Payments
Clinical Trials Icon Clinical Trials
Adverse Event Report Icon Adverse Event Report
Other top medicines used to treat Lymphoma